Immediate Impact
40 standout
Citing Papers
Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
2025 Standout
Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases
2025 Standout
Works of Ivan Staykov being referenced
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ivan Staykov | 253 | 98 | 102 | 101 | 5 | 283 | |
| Ena Singh | 229 | 64 | 70 | 114 | 7 | 311 | |
| Gerd R. Burmester | 144 | 33 | 167 | 53 | 4 | 293 | |
| Suyeon Kim | 153 | 58 | 56 | 65 | 5 | 258 | |
| A Lanzon | 181 | 70 | 62 | 74 | 2 | 202 | |
| Mieke F. Pouw | 137 | 27 | 120 | 10 | 6 | 276 | |
| René-Marc Flipo | 197 | 21 | 110 | 15 | 6 | 309 | |
| Véronique Lamarque | 182 | 19 | 55 | 20 | 7 | 277 | |
| Nashla Barroso | 109 | 10 | 106 | 7 | 7 | 318 | |
| Shu Li | 253 | 12 | 57 | 21 | 5 | 300 | |
| Emily Davies | 112 | 14 | 30 | 24 | 8 | 248 |
All Works
Loading papers...